Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss		$ (165,614)	$ (9,827)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization		706	195
Amortization of right-of-use asset		230	110
Accretion of discounts on marketable securities		(890)
Share-based compensation expense		5,386	2,257
Charge for purchase of in-process research and development assets	$ 6,312	118,266
Changes in operating assets and liabilities:
Prepaid expenses and other assets		877	1,216
Accounts payable		2,364	1,276
Accrued expenses and other current liabilities		7,568	(33)
Deferred revenue		(3,393)	23,373
Operating lease liabilities		(67)	(62)
Net cash (used in) provided by operating activities		(34,567)	18,505
Cash flows from investing activities:
Purchases of in-process research and development assets		(41,723)
Purchases of marketable securities		(112,688)
Maturities of marketable securities		40,000
Purchases of property and equipment		(4,508)	(446)
Net cash used in investing activities		(118,919)	(446)
Cash flows from financing activities:
Proceeds from public offering		230,002
Payment of offering costs		(14,624)
Proceeds from exercise of stock options		1,030
Proceeds from exercise of common stock warrants	300	3,731
Proceeds from issuance of common stock under ATM, net			34
Net cash provided by financing activities		220,139	34
Net increase in cash and cash equivalents and restricted cash		66,653	18,093
Cash and cash equivalents and restricted cash at beginning of period		98,779	20,423
Cash and cash equivalents and restricted cash at end of period	165,432	165,432	38,516
Reconciliation of cash and cash equivalents and restricted cash:
Cash and cash equivalents	165,332	165,332	38,416
Restricted cash	100	100	100
Total cash, cash equivalents, and restricted cash	$ 165,432	165,432	38,516
Supplemental disclosures of non-cash investing and financing activities:
Issuance of common stock in exchange for in-process research and development assets		74,033
Net liabilities assumed from purchases of in-process research and development assets		2,041
Purchase of in-process research and development assets in accounts payable		469
Right-of-use assets obtained in exchange for operating lease liabilities		1,189
Issuance of common stock to certain board of directors in lieu of accrued compensation			221
Offering costs in accounts payable and accrued expenses and other current liabilities		204	100
Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities		$ 1,236	$ 271